Summary

The United Kingdom monkeypox therapeutics market is projected to register growth at a formidable rate during the forecast period, 2023-2027. The market growth can be attributed to the rising incidences of monkeypox in the country and expanding population with weak immunity.
Monkeypox is a virus with a rapid pace of dissemination. According to the World Health Organization, the illness has a 3-6% death rate and causes fever, excruciating headaches, swollen lymph nodes, and other symptoms (WHO). Through close contact with respiratory secretions and skin lesions, the disease can be transferred from one person to another. Generally, prolonged face-to-face contact is necessary for the transmission of respiratory droplet particles, putting health workers, household members, and other close contacts of active cases at risk.
The rapid spread of monkeypox is boosting the market's growth by driving the demand for emergency medications for timely and efficient treatment. Additionally, researchers around the United Kingdom are constantly working to create pharmaceuticals in large quantities so that more patients can avail them. To enable the development of new drugs to stop the spread of monkeypox around the world, research and development operations need to make significant expenditures on cutting-edge machinery and technologies.
Some of the primary growth-inducing elements for the monkeypox treatments market are the expanding infrastructure and the simple accessibility to healthcare facilities. The United Kingdom provides its residents with modern, state-of-the-art healthcare facilities that raise awareness of a variety of disorders. Additionally, the necessity to get tested if experiencing any symptoms is driven by the public's growing knowledge of the monkeypox virus. This increases the need for hospitals or clinics to provide quality medical care.
The United Kingdom monkeypox therapeutics market is segmented on the basis of treatment, end user, regional distribution, and competitive landscape. Based on end user, the market is divided into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospital segment is anticipated to dominate the United Kingdom monkeypox therapeutics market, owing to the increasing number of patients getting admitted to the hospital to seek treatment for the virus rather than in other healthcare systems.
Major players operating in the United Kingdom monkey therapeutics market are Chimerix UK Limited, SIGA Technologies, Inc., Emergent BioSolutions UK Ltd., Bavarian Nordic A/S, Mylan N.V., Olon S.p.A., Teva UK Limited, among others.
Years considered for this report:
Historical Years: 2017-2020
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2023–2027
Objective of the Study:
• To analyze the historical growth in the market size of the United Kingdom monkeypox therapeutics from 2017 to 2021.
• To estimate and forecast the market size of United Kingdom monkeypox therapeutics market from 2023 to 2027 and growth rate until 2027.
• To classify and forecast the United Kingdom monkeypox therapeutics market based on treatment, end user, region, and company.
• To identify the dominant region or segment in the United Kingdom monkeypox therapeutics market.
• To identify drivers and challenges for the United Kingdom monkeypox therapeutics market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the United Kingdom monkeypox therapeutics market.
• To identify and analyze the profiles of leading players operating in the United Kingdom monkeypox therapeutics market.
• To identify key sustainable strategies adopted by market players in United Kingdom monkeypox therapeutics market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the service providers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the service providers and presence of all major players across the country.
TechSci Research calculated the market size of the United Kingdom monkeypox therapeutics market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as service providers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, United Kingdom monkeypox therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• United Kingdom Monkeypox Therapeutics Market, By Treatment:
o Smallpox Vaccine
o Antivirals
o Vaccinia Immune Globulin (VIG)
• United Kingdom Monkeypox Therapeutics Market, By End User:
o Hospitals
o Specialty Clinics
o Ambulatory Surgical Centers
o Others
• United Kingdom Monkeypox Therapeutics Market, By Region:
o London
o Southeast
o East Anglia
o Scotland
o Southwest
o East Midlands
o Yorkshire & Humberside
o Rest of United Kingdom

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in United Kingdom monkeypox therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
o Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on United Kingdom Monkeypox Therapeutics Market
4. Executive Summary
5. Voice of Customer
6. United Kingdom Monkeypox Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
6.2.3. By Region
6.2.4. By Company (2021)
6.3. Product Market Map
7. London Monkeypox Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By End User
8. East Anglia Monkeypox Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By End User
9. Southwest Monkeypox Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By End User
10. Southeast Monkeypox Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment
10.2.2. By End User
11. Scotland Monkeypox Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Treatment
11.2.2. By End User
12. East Midlands Monkeypox Therapeutics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Treatment
12.2.2. By End User
13. Yorkshire & Humberside Monkeypox Therapeutics Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Treatment
13.2.2. By End User
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. Policy & Regulatory Landscape
17. Import-Export Analysis
18. United Kingdom Economic Profile
19. Competitive Landscape
19.1. Chimerix UK Limited
19.2. SIGA Technologies, Inc.
19.3. Emergent BioSolutions UK Ltd.
19.4. Bavarian Nordic A/S
19.5. Mylan N.V.
19.6. Olon S.p.A.
19.7. Teva UK Limited
20. Strategic Recommendations